ArticleFrontiers in oncology2025
Identification of risk factors for high-risk dedifferentiation in papillary thyroid carcinoma and construction of discriminative model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We initially found that the thyroid differentiation score (TDS) was associated with the prognosis of papillary thyroid carcinoma (PTC) patients. Therefore, this study aimed to investigate the influencing factors and construct a discriminative model of high-risk dedifferentiation, and to explore the possible mechanisms. Methods: Data were sourced from the TCGA database. The influences of the TDS, tumor mutation burden, and immune score on the progression-free interval (PFI) were assessed by the Kaplan-Meier method and multivariable Cox regression. Then, logistic regression analyses were utilized to explore the factors of dedifferentiation and a nomogram model was conducted. Additionally, differentially expressed genes (DEGs) were identified using Results: This study included 391 PTC patients. After analyzing the influences of the three indicators on survival, only TDS showed an association with PFI. Multivariable logistic analysis revealed that the disease duration and PTC subtypes influenced dedifferentiation. The nomogram model based on these two variables showed improved discriminative capability. The study identified 17 overlapping DEGs associated with the dedifferentiation and three primary enrichment pathways, with complement and coagulation cascade pathways being the most significant ( Conclusion: This research may contribute to promising identifying high-risk dedifferentiated PTC and also provide a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.